Frequency Therapeutics Inc (NASDAQ: FREQ) stock plunges in the premarket after reporting topline day-90 data from its Phase 2a study (FX-322-202) evaluating the company's lead product candidate FX-322 ...
Top-Line Results Show Consistent Drug Entry in All Patients WOBURN, Mass.--(BUSINESS WIRE)-- Frequency Therapeutics, Inc. (Nasdaq: FREQ), today announced top-line data from an exploratory clinical ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results